Hints and tips:
Related Special Reports
...Pfizer products such as Paxlovid, combined Covid and flu test Lucira, and recently approved migraine nasal spray Zavzpret will be available on the site....
...Ogilvy, which has previously worked with a host of pharma groups including Pfizer and Johnson & Johnson, is launching a business that offers vetted influencers to talk about illnesses and possible solutions...
...Pfizer said: “We are confident in our IP position around Comirnaty and intend to vigorously defend against these claims.”...
...Pfizer is gearing up to launch its first-ever gene therapy at a list price of $3.5mn, after US regulators approved the treatment for a rare blood clotting disorder on Friday....
...BioNTech and Pfizer have said the patents are invalid....
...But, 10 years this month after Pfizer arrived on the scene, the Frenchman has a fresh challenge: persuading investors that AstraZeneca’s best days are not behind it....
...Pfizer has now completely erased its gains from 2020 and 2021, despite co-developing a widely used vaccine alongside German biotechnology company BioNTech....
...Pfizer reported dwindling Covid-19 revenues and weak sales from other products on Tuesday, as it notched a steep drop in sales in 2023....
...Pfizer needs to convince investors that Covid-19 treatments are not its only source of success. So far, it has failed....
...In response to these concerns, Pfizer initiated a significant cost-cutting programme, worth at least $4bn....
...The US government arranged with Pfizer to return 7.9mn Paxlovid courses at the end of 2023, at an estimated cost to the company of $4.2bn....
...Stocks like Pfizer, J&J and Sanofi are diversified enough for falling expectations around Covid vaccines to not matter overly....
...Read more on Pfizer here...
...Pfizer will not take the twice-daily formulation into late-stage trials but will focus on developing a pill to be taken once a day....
...Data on Pfizer’s once-daily oral pill is expected in the first half of 2024. Its shares fell 4.3 per cent lower before the open in New York. Read more on Pfizer here...
...wants a pivot in the biotech’s sales strategy for its Covid-19 shot, which is based on traditional vaccine technology, to target older people unnerved by rare side effects associated with mRNA jabs from Pfizer...
...It has been superseded by BioNTech/Pfizer and Moderna’s vaccines which were developed using mRNA technology and have become more broadly used worldwide. Read more here...
...AstraZeneca’s vaccine has been superseded by jabs from BioNTech/Pfizer and Moderna, which were developed using mRNA technology and have become the most used worldwide....
...Pharmaceuticals groups Pfizer and Moderna, which have both faced criticism from fringe groups over their Covid-19 vaccines, also spent heavily on security for their CEOs last year....
...Andrea Chiarello, Pfizer’s head of EU government affairs, said drugmakers needed more encouragement to discover new antimicrobials and develop drugs....
...Pfizer swung to a loss in the third quarter after a $5.6bn inventory write-off related to its Covid-19 antiviral and vaccine....
...Its vaccine, a more traditional protein-based formulation combined with an adjuvant to boost its effectiveness, has been pitched to patients as a counterpoint to mRNA jabs from BioNTech/Pfizer and Moderna...
...At one point pharmaceutical company Pfizer even set out a “no jerks” policy....
...Pfizer revised its full-year revenue guidance to a range between $58bn and $61bn, down from $67bn-$70bn, “solely due to Covid products”, it said....
...Panuwat’s company, Medivation, was bought in 2016 by Pfizer for $14bn. But the stock he purchased at the time was not that of Medivation....
International Edition